Saturday 17 October 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.96
0.05
+2.62%
Follow XTLB
| Jun '25 | Sep '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.70 | 0.81 | 11.43 | 9.93 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 13.37 | 0.00 | |
Debt/Assets |
12.04% | 1.81% | 0.00% | 0.00% | |
Debt/Equity |
(1.83) | 0.03 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | — | |
Interest Coverage |
— | — | (10.94) | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | — | |
Intangible Assets out of Total Assets |
0.00 | 0.76 | 0.13 | 0.16 | |
Free Cash Flow per Share |
— | — | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 1.72 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 1.99 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 1.99 | 0.00 | |
Free Cash Flow |
— | — | — | — | |
Working Capital |
(0.23) | (0.48) | 2.33 | 1.84 | |
Net Current Asset Value |
(0.23) | (1.58) | 2.33 | 1.84 | |
| Other line items | |||||
Quick Ratio |
0.46 | 0.75 | 11.16 | 9.74 | |
Revenue per Share |
— | — | 0.00 | — | |
Operating CF per Share |
— | — | 0.00 | — | |
Capex per Share |
— | — | 0.00 | — | |
Average Receivables |
0.17 | 0.17 | 0.19 | — | |
Average Payables |
0.40 | 0.36 | 0.23 | 0.20 | |
Average Assets |
1.69 | 6.07 | 3.13 | 3.31 | |
Average Common Equity |
1.23 | 4.21 | 2.89 | 3.11 |
Columns are period end dates